Huma and Tamer bring digital 'hospital at home' platform to the Kingdom of Saudi Arabia to tackle diabetes and cardiovascular disease - Seite 2

Dr Fayad Dandashi, CEO Tamer Healthcare, said: "Tamer is delighted to be able to offer this leading technology. We have seen the impact that Huma's technology has had in other countries, and we want to ensure that everyone in the Kingdom has access to this world-leading service. We work with every hospital in the Kingdom and believe this can make a real difference to patients and clinicians. We will start by helping people manage chronic conditions such as cardiovascular disease and diabetes, but are also seeking to implement a true 'hospital at home' service across the Kingdom that can support other diseases and areas of medicine such as surgery, dialysis etc. Then by combining with academic partners and driving research, we hope to move into even more proactive and predictive care."

Dan Vahdat, CEO and Founder of Huma, said: "Our technology today is changing millions of lives around the world, and we are extremely proud that people in the Kingdom of Saudi Arabia will soon be able to benefit from it. Working with Tamer, we look forward to helping everyone in the Kingdom to live longer, fuller lives."

About Tamer

Tamer Group is a leading healthcare, beauty care, prestige products, fast-moving consumer goods, and third-party logistics company that caters to the Saudi and Middle Eastern communities' rising demands. Importing, distribution, promotion, marketing, and manufacturing are the Group's main businesses.

Tamer Group, based in Jeddah, Saudi Arabia, provides services to many of the world's leading companies through a variety of agreements, partnerships, and joint ventures. Because of its distinctive approach to business, service, and customer portfolio, the company has established a special position in the Saudi market.

About Huma

Huma Therapeutics is a global digital health technology company headquartered in the UK that advances digital-first care delivery and research to help people live longer, fuller lives. Huma's award-winning modular platforms are used by more than 3,000 hospitals and clinics, with 1.8 million active users. Huma's offering works across different disease areas and powers:

• 'Hospitals at Home'
• Software as a Medical Device (SaMD) solutions
• DCT platform to support digital or hybrid studies

Huma's platform has been shown to almost double clinical capacity, reduce readmissions by over a third, enable better diversity, participant retention and protocol adherence, whilst allowing trials to run within weeks. Please visit www.huma.com and follow us on LinkedIn at Huma

References

1. World Health Organization, 2016: https://www.who.int/nmh/countries/sau_en.pdf
2. International Diabetes Federation's Diabetes Atlas, 10th edition 2021: https://diabetesatlas.org/data/en/country/174/sa.html
3. Huma Therapeutics wins Prix Galien USA 2021 award for Best Digital Health Product and HSJ Value Award 2021.
4. Data from 2021 pilot study. Full evaluation of the service is in preparation. 
5. NHSX report: https://www.nhsx.nhs.uk/covid-19-response/technology-nhs/huma-medopad-evaluation-remote-digital-care-platform/ The full report is available on request.
6. Obika, BD et al. (2021) Implementation of a mHealth solution to remotely monitor patients on a cardiac surgical waiting list: service evaluation JAMIA Open 4 (3) doi.org/10.1093/jamiaopen/ooab053

Logo - https://mma.prnewswire.com/media/1427908/Huma_Logo.jpg